secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-114730
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.
- Gross proceeds expected ~$85M; net proceeds ~$69.7M ($81.7M if over-allotment option exercised).
- Proceeds to fund clinical development of SAB-142 (anti-thymocyte immunoglobulin) for type 1 diabetes.
- Offering led by Jefferies, UBS, Citigroup, Barclays; expected to close March 19, 2026.
- 30-day over-allotment option for additional 3.31M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/0001193125-26-114730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/sabs-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-114730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer